自引率: 4.7%
被引量: 14297
通过率: 暂无数据
审稿周期: 1.56
版面费用: 暂无数据
国人发稿量: 325
投稿须知/期刊简介:
Published by Elsevier Science. ISSN: 1567-5769.<br><br>Merger of International Journal of Immunopharmacology and Immunopharmacology. International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. Agents that activate genes or modify transcription and translation within the immune response. Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. Production, function and regulation of cytokines and their receptors. Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system. Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses. The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.
期刊描述简介:
Published by Elsevier Science. ISSN: 1567-5769. Merger of International Journal of Immunopharmacology and Immunopharmacology. International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. Agents that activate genes or modify transcription and translation within the immune response. Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. Production, function and regulation of cytokines and their receptors. Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system. Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses. The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.
-
RTA408 alleviates lipopolysaccharide-induced acute lung injury via inhibiting Bach1-mediated ferroptosis.
The approved traditional Asian medicine RTA408 (Omaveloxolone) has demonstrated potent anti-inflammatory properties in the treatment of Friedreich's ataxia. However, its effect on lipopolysaccharide (LPS)-induced acute lung injury (ALI) remains poorly understood. This study aims to evaluate the effect of RTA408 on LPS-induced ALI and elucidate its underlying mechanisms. In this study, in vivo experiments demonstrated that RTA408 significantly ameliorated LPS-induced mouse ALI, characterized by reduced pathological damage and neutrophil infiltration as well as decreased lung edema of murine lung tissues. Moreover, LPS administration induced ferroptosis in ALI mice, evidenced by increased MDA levels, reduced GSH and SOD activity, and decreased expression of ferroptosis repressors (GPX4 and SLC7A11), whereas RTA408 reversed these changes. Consistently, RTA408 reduced ferroptosis and improved cell damage in LPS-stimulated MLE-12 cells, as evidenced by decreased ROS and MDA levels, increased SOD, GSH activity and ferroptosis repressors expression. Meanwhile, the protective effective of RTA408 on LPS-induced oxidative damage was blocked by ferroptosis inhibitor ferrostatin-1 (Fer-1). Mechanistic studies demonstrated that RTA408 inhibited the expression and nuclear translocation of Bach1, and the anti-ferroptosis effect was diminished by Bach1 siRNA or Bach1 knockout (Bach1-/-) mice. Furthermore, Bach1-/- mice exhibited attenuated ALI induced by LPS compared to wild-type (WT) mice, and the protective effect of RTA408 on LPS-challenged ALI was not observed in Bach1-/- mice. In conclusion, our data suggested that RTA408 alleviates LPS-induced ALI by interfering Bach1-mediated ferroptosis and might be a novel candidate for LPS-induced ALI/ARDS therapy.
被引量:- 发表:1970
-
Taurochenodeoxycholic acid ameliorates the Staphylococcus aureus infection-induced acute lung injury through toll-like receptor 2 in mice.
被引量:- 发表:1970
-
Expression of integrin α4β1 and α4β7 on B cells correlates with autoimmune responses in Graves' disease.
被引量:- 发表:1970
-
Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique.
被引量:- 发表:1970
-
GDF11 promotes osteogenic/odontogenic differentiation of dental pulp stem cells to accelerate dentin restoration via modulating SIRT3/FOXO3-mediated mitophagy.
被引量:- 发表:1970